Leisha Ann Emens
#165,151
Most Influential Person Now
Leisha Ann Emens's AcademicInfluence.com Rankings
Leisha Ann Emensphilosophy Degrees
Philosophy
#9685
World Rank
#13280
Historical Rank
Logic
#6654
World Rank
#8191
Historical Rank
Leisha Ann Emensbiology Degrees
Biology
#13341
World Rank
#16886
Historical Rank
Immunology
#920
World Rank
#944
Historical Rank
Download Badge
Philosophy Biology
Leisha Ann Emens's Degrees
- Doctorate Medicine University of Pennsylvania
- PhD Immunology University of Pennsylvania
Why Is Leisha Ann Emens Influential?
(Suggest an Edit or Addition)Leisha Ann Emens's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer (2018) (1567)
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (616)
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies (2015) (522)
- Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. (2001) (479)
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study (2017) (478)
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study (2019) (464)
- Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response (2005) (424)
- Breast Cancer Immunotherapy: Facts and Hopes (2017) (418)
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. (2017) (398)
- Targeting adenosine for cancer immunotherapy (2018) (314)
- Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood (2012) (305)
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. (2016) (278)
- Antagonists of PD-1 and PD-L1 in Cancer Treatment. (2015) (254)
- Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. (2009) (231)
- Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. (2009) (214)
- Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) (2015) (197)
- A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism (2007) (194)
- Chemoimmunotherapy: reengineering tumor immunity (2013) (185)
- Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. (2005) (171)
- The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. (2001) (169)
- Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade (2012) (150)
- Hepatocyte nuclear factor 1 alpha is expressed in a hamster insulinoma line and transactivates the rat insulin I gene. (1992) (139)
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors (2019) (136)
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. (2020) (132)
- Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. (2010) (124)
- The immune microenvironment of breast ductal carcinoma in situ (2016) (123)
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. (2021) (122)
- Immune targeting in breast cancer. (2015) (120)
- Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study (2021) (117)
- A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice (2017) (104)
- Trastuzumab: Targeted Therapy for the Management of HER-2/neu-Overexpressing Metastatic Breast Cancer (2005) (102)
- HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice1 (2003) (102)
- OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen1 (2006) (99)
- Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses (2017) (99)
- Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. (2013) (96)
- Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 (2019) (95)
- Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. (2008) (88)
- Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. (2005) (87)
- Chemotherapy: friend or foe to cancer vaccines? (2001) (85)
- Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. (2019) (83)
- Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. (2019) (81)
- The follow-up of breast cancer. (2003) (77)
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer (2019) (75)
- The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages. (2010) (74)
- Cancer vaccines: on the threshold of success (2008) (72)
- Trastuzumab in breast cancer. (2004) (70)
- IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (67)
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer (2014) (67)
- PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer (2021) (62)
- GM-CSF-secreting vaccines for solid tumors: moving forward. (2010) (62)
- HER2-directed therapy for metastatic breast cancer. (2013) (60)
- Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
- A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer (2012) (58)
- Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab +nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer (2019) (57)
- The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome (2018) (56)
- Toward integrative cancer immunotherapy: targeting the tumor microenvironment (2012) (56)
- Chemotherapy and tumor immunity: an unexpected collaboration. (2008) (55)
- Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors (2019) (53)
- Targeting the programmed cell death-1 pathway in breast and ovarian cancer (2016) (51)
- Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? (2001) (49)
- The myc intron-binding polypeptide associates with RFX1 in vivo and binds to the major histocompatibility complex class II promoter region, to the hepatitis B virus enhancer, and to regulatory regions of several distinct viral genes (1995) (46)
- Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. (2018) (46)
- Cancer Vaccines: An Old Idea Comes of Age (2003) (46)
- Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC). (2017) (44)
- Roadmap to a Better Therapeutic Tumor Vaccine (2006) (44)
- Cancer immunotherapy trials: leading a paradigm shift in drug development (2016) (43)
- Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide (2019) (42)
- Racial disparities in the rate of cardiotoxicity of HER2‐targeted therapies among women with early breast cancer (2018) (40)
- Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC) (2016) (40)
- A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. (2004) (39)
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply. (2019) (35)
- Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. (2017) (34)
- A New Twist on Autologous Cancer Vaccines (2003) (33)
- LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (2020) (30)
- Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. (2019) (30)
- Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer (2020) (30)
- Regression of splenic lymphoma after treatment of hepatitis C virus infection. (2002) (30)
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. (2020) (30)
- Specific immunotherapy in ovarian cancer: a systematic review. (2016) (29)
- Adjuvant hormonal therapy for premenopausal women with breast cancer. (2003) (28)
- Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. (2017) (28)
- PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast (2017) (28)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer (2021) (28)
- Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole (2011) (28)
- Chemoimmunotherapy (2010) (28)
- Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors (2017) (27)
- GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. (2007) (27)
- A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway. (2013) (26)
- The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. (2021) (26)
- Sorafenib combined with HER‐2 targeted vaccination can promote effective T cell immunity in vivo (2017) (23)
- IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). (2016) (23)
- Toward a breast cancer vaccine: work in progress. (2003) (22)
- Emerging immunotherapies in ovarian cancer. (2015) (22)
- The evolving management of metastatic triple negative breast cancer. (2020) (21)
- Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab (2019) (20)
- A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors. (2017) (20)
- Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. (2004) (19)
- Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. (2005) (19)
- Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer (2021) (18)
- Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer (2011) (18)
- Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 (2020) (18)
- Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis (2019) (17)
- GM-CSF-secreting vaccines for solid tumors. (2009) (16)
- A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. (2011) (16)
- Cytokine gene-modified cell-based cancer vaccines. (2002) (16)
- To Live or Not to Live–THAT Depends on GAGE? (2002) (15)
- African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. (2009) (15)
- Immunotherapy in Triple-Negative Breast Cancer. (2021) (14)
- OX 40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD 8 T Cell Tolerance to an Endogenous Tumor Antigen 1 (2005) (14)
- Cancer vaccines in combination with multimodality therapy. (2005) (13)
- Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. (2010) (13)
- Cancer Immunotherapy Principles and Practice (2018) (13)
- Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. (2009) (12)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) (2018) (12)
- Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer. (2019) (12)
- Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies (2021) (11)
- Reflex Estrogen Receptor/Progesterone Receptor/Human Epidermal Growth Factor Receptor 2 (ER/PR/Her2) Analysis of Breast Cancers in Needle Core Biopsy Specimens Dramatically Increases Health Care Costs (2015) (11)
- Current and emerging biologic therapies for triple negative breast cancer (2020) (10)
- IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2018) (10)
- Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) (2016) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors (2020) (9)
- Re-purposing cancer therapeutics for breast cancer immunotherapy (2012) (9)
- HER 2-Directed Therapy for Metastatic Breast Cancer (2017) (8)
- 209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors (2021) (8)
- Survivin' Cancer (2004) (8)
- Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor–Positive Breast Cancer (2021) (8)
- Cancer vaccines: toward the next revolution in cancer therapy. (2006) (8)
- Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. (2021) (8)
- Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y (2016) (7)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy) (2021) (7)
- Immunotherapy and Cancer Therapeutics: Why Partner? (2007) (7)
- Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy. (2021) (7)
- Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors (2021) (7)
- It’s TIME for a biomarker-driven approach to cancer immunotherapy (2016) (7)
- Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC) (2022) (6)
- Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). (2019) (5)
- Postoperative endocrine therapy for invasive breast cancer. (2009) (5)
- The dawn of immunotherapy for breast cancer. (2019) (5)
- Invasive Lobular Carcinoma of the Male Breast: A Rare Histology in an Uncommon Disease (2009) (5)
- A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer. (2022) (5)
- 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors (2020) (5)
- Abstract PD1-05: Atezolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer: Safety and biomarker outcomes from a multi-cohort Phase Ib st (2020) (4)
- Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer (2022) (4)
- 329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer (2021) (4)
- Abstract P2-09-13: Molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo) (2018) (4)
- A clinical study of tremelimumab alone or in combination with olaparib in patients with advanced epithelial ovarian cancer. (2020) (4)
- 317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors (2020) (4)
- Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer (2019) (4)
- Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012 (2013) (4)
- Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries (2019) (3)
- Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine (2008) (3)
- Abstract CT001: Biomarkers of systemic inflammation associated to reduced clinical activity of atezolizumab monotherapy in patients with metastatic triple negative breast cancer (2019) (3)
- Abstract 4749: Cyclophosphamide induces dose dependent apoptosis of CD4+FoxP3+ regulatory T cells relative to CD4+FoxP3- effector T cells in breast cancer patients. (2013) (3)
- CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy (2022) (3)
- Immunotherapy for breast cancer: is it feasible? (2015) (3)
- Advances in Brief The Collaboration of Both Humoral and Cellular HER-2 / neu-targeted Immune Responses Is Required for the Complete Eradication of HER-2 / neu-expressing Tumors 1 (2001) (3)
- New findings about endocrine therapy for breast cancer. (2003) (2)
- Abstract 3985: Sorafenib modulates macrophages to promote T helper type 1 immunity. (2013) (2)
- Report on the Third FDA–AACR Oncology Dose-Finding Workshop (2017) (2)
- Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers (2022) (2)
- Towards a therapeutic breast cancer vaccine: the next steps (2005) (2)
- A Phase I Toxicity and Feasibility Trial of Sequential Dose-Dense Induction Chemotherapy with Doxorubicin, Paclitaxel, and 5-Fluorouracil Followed by High Dose Consolidation for High-Risk Primary Breast Cancer (2002) (2)
- IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (2)
- Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients (2021) (2)
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (2)
- Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen (2020) (2)
- Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC) (2022) (1)
- AVascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-BasedMechanism (2007) (1)
- Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors (2021) (1)
- Immunotherapy and Cancer Therapeutics: A Rich Partnership (2013) (1)
- Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis (2022) (1)
- Chemotherapy--A Viable Partner for Cancer Immunotherapy? (2015) (1)
- Enhancement of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine by Immunomodulatory Doses of Cyclophosphamide and Doxorubicin (2003) (1)
- Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (1)
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (1)
- STING signaling: a key to therapeutic tumor immunity. (2018) (1)
- Toward integrative cancer immunotherapy: targeting the tumor microenvironment (2012) (0)
- Abstract 3748: Development of anti-human mesothelin chimeric antigen receptor (CAR) messenger RNA (mRNA) transfected peripheral blood mononuclear cells (CARMA) for the treatment of mesothelin-expressing cancers (2017) (0)
- Biomarkers of the PD-1 Pathway in Breast Carcinomas (2017) (0)
- Abstract PS1-10: Outcomes after sentinel lymph node biopsy and radiation therapy in women over 70 years old with ER+, HER2-, clinically node negative breast cancer (2021) (0)
- Abstract MS1-2: MS1-2 Breast cancer immunotherapy: Building on clinical success (2017) (0)
- Abstract 2993: STING signaling in breast tumor microenvironment modulates immune checkpoint blockade efficacy in the neu-N mouse model of breast cancer (2017) (0)
- 127TiP Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC) (2021) (0)
- Abstract OT-32-01: A phase 2, open-label study of bintrafusp alfa monotherapy in patients withHMGA2-expressing triple-negative breast cancer (2021) (0)
- Abstract 2875: Evidence of immunosuppression in patients with breast ductal carcinoma in situ (2023) (0)
- Mechanisms of action and acquired resistance to atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC). (2022) (0)
- Trastuzumab: Molecularly targeted therapy for early and metastatic HER-2/neu-positive breast cancer (2006) (0)
- Jump-Starting Tumor Immunity with Breast Cancer Therapeutics (2007) (0)
- Abstract OT1-18-08: Randomized phase II trial of pembrolizumab/carboplatin vs. carboplatin alone for breast cancer with chest wall recurrence: TBCRC044 (2022) (0)
- Pathologic complete response (pCR) to preoperative sequential doxorubicin/cyclophosphamide (AC) and taxane (AC-T) or AC followed by paclitaxel and trastuzumab (AC-TH) in stage II-III HER2-positive breast cancer (2008) (0)
- Gene-Modified Tumor-Cell Vaccines (2004) (0)
- T Cells and Antigen Recognition (2007) (0)
- Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice (2021) (0)
- Dr. Emens Discusses Overall Survival in HER2+ Breast Cancer (2019) (0)
- Abstract 3991: Profiling the immune tumor microenvironment in primary and recurrent epithelial ovarian cancer (2017) (0)
- OP-JNCI210068 1601..1603 (2021) (0)
- A Novel Approach to Journal Club Designed to Immerse Trainees in a Peer-Review Process to Critically Evaluate Oncology Manuscripts (2016) (0)
- QSPIO-TNBC: A Quantitative Systems Pharmacology Platform in Immune-Oncology for Triple-Negative Breast Cancer (2021) (0)
- Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC) (2019) (0)
- Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (0)
- 12-month uptake of PD-L1 testing and atezolizumab (atezo) + nab-paclitaxel (nab-pac) treatment in metastatic triple-negative breast cancer (mTNBC) following accelerated FDA-approval in the United States. (2020) (0)
- Direct activation of STING in the tumor microenvironment partially overcomes immune tolerance in neu-N transgenic mice (2015) (0)
- 750 poster COSMETIC OUTCOME AFTER PARTIAL BREAST IRRADIATION WITH CONCURRENT CHEMOTHERAPY IN EARLY-STAGE BREAST CANCER (2011) (0)
- Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry. (2020) (0)
- A Novel Approach to Journal Club Designed to Immerse Trainees in a Peer-Review Process to Critically Evaluate Oncology Manuscripts (2016) (0)
- Hepatocyte nuclear factor laisexpressed inahamster insulinoma line andtransactivates theratinsulin Igene (insulin geneexpression/transcription/tissue specificty) (1992) (0)
- Abstract P4-13-08: Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2− metastatic breast cancer in the real-world setting (2019) (0)
- Impaired Ca++ mobilization in rituximab-resistant cells is associated with changes in the structure of CD20 antigen and downregulation of Bax/Bak pro-apoptotic proteins (2006) (0)
- Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer (2015) (0)
- Whole-cell vaccines (2017) (0)
- IMpassion130: Efficacy in immune biomarker subgroups of atezolizumab plus nab-paclitaxel in patients with triple-negative BC (2019) (0)
- Manipulating Immunological Checkpoints to Maximize Antitumor Immunity (2006) (0)
- The monoclonal antibody 7.16.4 sequenced with cyclophosphamide-modulated vaccination maximizes tumor immunity and tumor-free survival in tumor-bearing tolerant neu-N mice (2008) (0)
- Quiescent cancer cells: Therapeutic targets to overcome immunotherapy resistance? (2022) (0)
- Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044. (2021) (0)
- Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs). (2022) (0)
- Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial. (2020) (0)
- Abstract 2412: Sorafenib can be effectively combined with GM-CSF secreting cellular immunotherapy in a mouse model of HER-2+ breast cancer (2010) (0)
- Abstract PS9-15: Utilizing education to strengthen oncologist' understanding of immunotherapy in triple negative breast cancer (2021) (0)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy) (2021) (0)
- Abstract PD14-05: Genomic profiling and clinical outcomes with first-line atezolizumab andnab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial (2021) (0)
- Editorial (2006) (0)
- Mucosa-Associated Lymphoid Tissue Disease in the Lung: When Should It Be Treated as Lymphoma? (2003) (0)
- Abstract P2-16-26: Mixed invasive ductal and lobular carcinoma (IDC/L) behaves similarly to invasive lobular carcinoma (ILC) with regard to neoadjuvant chemotherapy response and metastatic dissemination (2020) (0)
- 136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC (2016) (0)
- Multi-targeted therapy with a HER-2/neu-specific vaccine and a VEGF-R2 inhibitor enhances anti-tumor immunity (2006) (0)
- Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers (2022) (0)
- Breast Cancer Immunotherapy (2021) (0)
- Abstract OT-13-09: Translational breast cancer research consortium 044 trial: Randomized phase 2 study of pembrolizumab and carboplatin versus carboplatin alone for chest wall recurrence of breast cancer (2021) (0)
- Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab (2022) (0)
- Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993. (2021) (0)
- 767 poster PARTIAL BREAST IRRADIATION WITH CONCURRENT DOSE DENSE DOXORUBICIN & CYCLOPHOSPHAMIDE: LATE TOXICITY & RECURRENCE (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Leisha Ann Emens?
Leisha Ann Emens is affiliated with the following schools:
